Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research and development over the same period, according to a report released Thursday by the House Committee on Oversight and Reform.

For the same time period, the report notes that the companies’ top executives earned more as they raised drug prices, with salaries growing by 14% and compensation totaling $3.2 billion. In addition, findings show research and development budgets were spent “on finding ways to suppress generic and biosimilar competition while continuing to raise prices, rather than on innovative research.”
 

Related News Articles

Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The Food and Drug Administration recently disclosed dozens of warning letters sent to drug companies that accuse them of using misleading or deceptive…
Headline
President Trump Sept. 10 signed a memorandum directing the Department of Health and Human Services and Food and Drug Administration to require drug companies…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…
Headline
The Food and Drug Administration Aug. 7 announced a new program to help improve the domestic pharmaceutical supply chain by increasing regulatory…